Thomas Valente is a Psychiatry physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2020 Talley Rd
Leesburg, FL 347483426
Telephone
352-315-7810Provider last certified this registry record 14 Feb 2024.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Neurocrine BioSciences, Inc.Program year2025104 payments$71,655openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202582 payments$56,308openpaymentsdata.cms.gov ↗
- ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)Program year202573 payments$48,134openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.4%Atypical Antipsychotic27.9%Aripiprazole16%Quetiapine Fumarate12%Risperidone10%Rexulti9%Olanzapine8%Invega Sustenna8%Lurasidone Hcl7%Vraylar6%Clozapine4%Abilify Maintena3%Lybalvi3%Caplyta2%Ziprasidone Hcl2%Paliperidone Er2%Asenapine Maleate1%Invega Trinza1%Olanzapine Odt1%Abilify Asimtufii1%Nuplazid1%Clozapine Odt1%Quetiapine Fumarate Er1%Zyprexa Relprevv1%Part D<11 patientsSSRI11.9%Trazodone Hcl38%Sertraline Hcl16%Fluoxetine Hcl14%Escitalopram Oxalate13%Citalopram Hbr9%Fluvoxamine Maleate5%Paroxetine Hcl5%Part D<11 patients+ 29 more classes in this area
Cardiovascular
1.9%alpha-Adrenergic Blocker0.6%Prazosin Hcl100%Part D<11 patientsCentral alpha-2 Adrenergic Agonist0.6%Clonidine Hcl59%Guanfacine Hcl41%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
0.7%Biguanide (metformin)0.5%Metformin Hcl100%Part D<11 patientsProton pump inhibitor0.2%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2010–2012 per NIH RePORTER. The latest:
- INNOVATIVE IMPLEMENTATION RESEARCH METHODS CORE
University of Miami School of Medicine
FY2012$728,728P30DA027828 - INNOVATIVE IMPLEMENTATION RESEARCH METHODS CORE
University of Miami School of Medicine
FY2011$736,583P30DA027828
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”